Home  |  Contact

Cellosaurus ZR75-LTED (CVCL_YX86)

[Text version]

Cell line name ZR75-LTED
Synonyms ZR75 LTED; ZR75-Long Term Estrogen-Deprived
Accession CVCL_YX86
Resource Identification Initiative To cite this cell line use: ZR75-LTED (RRID:CVCL_YX86)
Comments Population: Caucasian.
Characteristics: Derived from parental cell line by long-term culture in the presence of RPMI-1640 medium containing 10% dextran charcoal stripped serum (DCC) (PubMed=26116361).
Sequence variations Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
Disease Invasive breast carcinoma of no special type (NCIt: C4194)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0588 (ZR-75-1)
Sex of cell Female
Age at sampling 63Y
Category Cancer cell line
Publications

PubMed=26116361; DOI=10.1158/1535-7163.MCT-15-0143
Ribas R., Pancholi S., Guest S.K., Marangoni E., Gao Q., Thuleau A., Simigdala N., Polanska U.M., Campbell H., Rani A., Liccardi G., Johnston S.R.D., Davies B.R., Dowsett M., Martin L.-A.
AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo.
Mol. Cancer Ther. 14:2035-2048(2015)

Cross-references
Other Wikidata; Q98136617
Entry history
Entry creation12-Mar-2020
Last entry update23-Sep-2021
Version number4